Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 24;7(1):vdaf082.
doi: 10.1093/noajnl/vdaf082. eCollection 2025 Jan-Dec.

Primary central nervous system lymphoma: Predictors of response to induction therapy and patterns of progression

Louis Cappelli  1 , Allison Kayne  2 , Jennifer Newman  3 , Ahmed Elguindy  4 , Narendranath Epperla  5 , Joshua D Palmer  4 , Ubaldo Martinez Outschoorn  6 , Pierluigi Porcu  6 , Wenyin Shi  1 , Iyad Alnahhas  7
Affiliations

Primary central nervous system lymphoma: Predictors of response to induction therapy and patterns of progression

Louis Cappelli et al. Neurooncol Adv. .

Abstract

Background: Primary central nervous system lymphoma (PCNSL) is a rare and aggressive variant of non-Hodgkin lymphoma. While PCNSL is often sensitive to induction high-dose methotrexate (HDMTX) based chemotherapy, recurrence rates remain high, approaching 50% within 5 years. The most common molecular alterations in PCNSL include mutations in MYD88 and CD79 and CDKN2A homozygous deletion. There are no predictive or prognostic molecular markers in PCNSL.

Methods: We conducted a retrospective review of 40 patients with PCNSL treated at Thomas Jefferson University and Ohio State University between 2011 and 2023. We created a clinically annotated database of patient characteristics and outcomes. For 13 patients whose paraffin-embedded tissue was available for analysis, Illumina's Infinium Global Diversity Array with Cytogenetics was used to make copy number change calls.

Results: The most commonly used induction chemotherapy regimens were HDMTX monotherapy and HDMTX with rituximab. The overall response rate to induction chemotherapy was 75%. A total of 25% had resistant disease to induction chemotherapy. The median follow-up was 20.3 months. The median progression-free survival for the entire cohort was 30.64 months (range 3.42-57.86 months); 2.56 months for the resistant group and 44.88 months for the sensitive group (P-value < .001). The median overall survival for the entire cohort was 64.8 months (range 41.47-88.13 months); 13.97 months for the resistant group and 81.43 months for the sensitive group (P-value = .046).

Conclusions: The initial response to induction chemotherapy is an important prognostic factor in PCNSL. There is a need for improved predictive biomarkers of response to treatment in PNCLS.

Keywords: CDKN2A; HDMTX; PCNSL; induction chemotherapy; relapse.

PubMed Disclaimer

Conflict of interest statement

Louis Cappelli: none declared. Allison Kayne: none declared. Jennifer Newman: none. 243 declared. Ahmed Elguindy: none declared. Narendranath Epperla: none declared. Joshua D. Palmer:. 244 grants from Genetech (Phase II clinical trial in HCRN network, outside submitted work), NIH R702. 245 (Photon vs Proton clinical study, outside submitted work), NIH R01CA269948 (Multi-institutional GBM. 246 imaging Artificial Intelligence study, outside submitted work), payments/honoraria from Varian Medical. 247 Systems, Novocure, and ICOTEC. Ubaldo Martinez Outschoorn: none declared. Pierluigi Porcu: none. 248 declared. Wenyin Shi: consulting fees from BrainLab, Novocure, Zai Lab, and Varian Medical System. Iyad. 249 Alnahhas: none declared.

Figures

Figure 1.
Figure 1.
(A) Local versus distant progression of PCNSL. (A) is an example of local tumor progression on MRI T1-post contrast (left pre-HDMTX; right post-HDMTX). The black borders correlate with the lesion after progression. (B) Local versus distant progression of PCNSL. (B) is an example of distant tumor progression on MRI T1-post contrast (left pre-HDMTX; right post-HDMTX). The black borders correlate with the lesion after progression.
See this image and copyright information in PMC

References

    1. Schaff LR, Grommes C.. Primary central nervous system lymphoma. Blood. 2022;140(9):971–979. - PMC - PubMed
    1. Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE.. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006;24(28):4570–4574. - PubMed
    1. DeAngelis LM, Yahalom J, Thaler HT, Kher U.. Combined modality therapy for primary CNS lymphoma. J Clin Oncol. 1992;10(4):635–643. - PubMed
    1. Ferreri AJ, Reni M, Foppoli M, et al. ; International Extranodal Lymphoma Study Group (IELSG). High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: A randomised phase 2 trial. Lancet. 2009;374(9700):1512–1520. - PubMed
    1. Omuro A, Correa DD, DeAngelis LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125(9):1403–1410. - PMC - PubMed

LinkOut - more resources